These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 29655611)

  • 41. Preclinical evaluation of
    Liu Q; Cai S; Ye J; Xie Q; Liu R; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1826-1840. PubMed ID: 38319321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and characterization of a novel
    Sui Y; Duan X; Zhang J; Chu Y; Yang X
    Bioorg Med Chem Lett; 2023 Jul; 91():129382. PubMed ID: 37348571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
    Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
    Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
    Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
    Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [
    Lu Q; Long Y; Fan K; Shen Z; Gai Y; Liu Q; Jiang D; Cai W; Wan C; Lan X
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4000-4013. PubMed ID: 35763056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of a [Al
    Al-Momani E; Israel I; Samnick S
    Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiochemistry and Preclinical PET Imaging of
    Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
    Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
    Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
    Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Basaco Bernabeu T; Mansi R; Del Pozzo L; Zanger S; Gaonkar RH; McDougall L; De Rose F; Jaafar-Thiel L; Herz M; Eiber M; Ulaner GA; Weber WA; Fani M
    J Nucl Med; 2024 Sep; 65(9):1427-1434. PubMed ID: 39025646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical translation of a PSMA inhibitor for
    Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer.
    Fu H; Lou K; He H; Wang Y; Mi Y; Li W; Chen L; Zhang Y; Yu C
    Eur J Nucl Med Mol Imaging; 2024 Aug; 51(10):2998-3008. PubMed ID: 37914976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
    Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
    Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
    Brand C; Longo VA; Groaning M; Weber WA; Reiner T
    Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and preclinical evaluation of an Al
    Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and preclinical evaluation of
    Hou H; Lin Y; Pan Y; Ma Y; Hou G; Sun X; Gao F
    Eur J Med Chem; 2024 Aug; 274():116545. PubMed ID: 38823263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results.
    Wurzer A; Pollmann J; Schmidt A; Reich D; Wester HJ; Notni J
    Mol Pharm; 2018 Sep; 15(9):4296-4302. PubMed ID: 30011372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
    Banerjee SR; Pullambhatla M; Byun Y; Nimmagadda S; Green G; Fox JJ; Horti A; Mease RC; Pomper MG
    J Med Chem; 2010 Jul; 53(14):5333-41. PubMed ID: 20568777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.